Tag: GlobeNewswire

PHILADELPHIA, Nov. 03, 2026 (GLOBE NEWSWIRE) — Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced its participation in the following upcoming investor conferences:

• Guggenheim’s 3rd Annual Healthcare Innovation Conference: Meetings with investors and a webcasted fireside chat at 9:00 a.m. ET on Tuesday, November 10, 2026, in Boston, MA.
• 2026 Jefferies Global Healthcare Conference in London: Meetings with investors and a webcasted fireside chat at 5:00 p.m. GMT (12:00 p.m. ET) on Wednesday, November 18, 2026, in London, UK.

The webcasted fireside chats will be accessible on the News and Events section of the Company’s website at www.cabalettabio.com. Archived replays will be available for 30 days.

About Cabaletta Bio
Cabaletta Bio (Nasdaq: CABA) is a late-stage clinical biotechnology company focused on developing and launching curative targeted cell therapies designed specifically for patients with autoimmune diseases. Cabaletta’s lead product candidate, rese-cel, is an investigational 4-1BB-containing fully human CD19-CAR T cell therapy being advanced across the RESET™ (REstoring SElf-Tolerance) clinical development program spanning multiple therapeutic areas, including rheumatology, neurology, and dermatology. Cabaletta Bio’s headquarters and labs are located in Philadelphia, PA. For more information, visit www.cabalettabio.com and connect with us on LinkedIn.

Contacts
Investors: investors@cabalettabio.com
Media: media@cabalettabio.com

– Founder & CEO Laura Niklason, M.D., Ph.D., to deliver invited talk on engineering the microenvironment to accelerate vascular regeneration.

– Two additional presentations to cover first-in-human Phase 2a study design and preclinical results for Humacyte’s investigational coronary tissue engineered vessel.

DURHAM, N.C., Nov. 03, 2026 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at a commercial scale, announced today that the Company’s regenerative medicine technology will be highlighted in three presentations at the American Heart Association (AHA) Scientific Sessions 2026. The conference will be taking place from November 6–9th at McCormick Place Convention Center in Chicago, Illinois.

AHA Scientific Sessions is one of the world’s largest gatherings of cardiovascular clinicians and scientists. Humacyte’s presentations include an invited talk by the company’s Founder, President and Chief Executive Officer, Laura Niklason, M.D., Ph.D., and two presentations highlighting Humacyte’s investigational coronary tissue engineered vessel (CTEV), a small-diameter bioengineered vessel for coronary artery bypass grafting (CABG).

“AHA brings together the cardiac surgeons and cardiologists who will ultimately decide whether an off-the-shelf conduit belongs in bypass surgery, and we are excited for them to see our preclinical data and our study design firsthand,” said Dr. Niklason. “Our approach is built on the idea that the body can repopulate an engineered vessel with a patient’s own cells. With the CTEV, we are taking the next step toward bringing bioengineered vascular technology to coronary bypass surgery through the first U.S. clinical trial of a bioengineered CABG conduit.”

Presentation details:

Invited Talk

• Title: Engineering the Microenvironment to Accelerate Vascular Regeneration
• Presenter: Laura E. Niklason, M.D., Ph.D., Founder and CEO, Humacyte, Inc.
• Date and time: Saturday, November 7, 2026, 10:15 AM CT
• Location: North Hall, Level 3, McCormick Place, Chicago

Clinical Study Design

• Title: First-in-Human Phase 2a Study Design of a Bioengineered Human Coronary Artery for Coronary Artery Bypass Grafting
• Presenters: John Alexander, M.D., M.H.S., Professor of Medicine/Cardiology, Duke Clinical Research Institute at Duke University and Alan Kypson, M.D., Cardiothoracic Surgeon, UNC Rex Hospital
• Date and time: Saturday, November 7, 2026, 3:57 PM CT
• Session/Location: Science and Technology Hall, Level 3, Clinical Science Zone 1, McCormick Place, Chicago

Preclinical CABG Results

• Title: Evaluation of Tissue Engineered Human Vessels in Porcine and Ovine Models of Coronary Artery Bypass Grafting
• Presenter: Robert Kirkton, Ph.D., Executive Director of New Product and Process Development, Humacyte, Inc.
• Date and time: Sunday, November 8, 2026, 9:15 AM CT
• Session/Location: Science and Technology Hall, Level 3, Clinical Science Zone 2, McCormick Place, Chicago

The CTEV is an investigational product and has not been approved for sale by the FDA or any other regulatory agency.

About Humacyte

Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Humacyte’s Biologics License Application for the acellular tissue engineered vessel (ATEV) in the vascular trauma indication was approved by the FDA in December 2024. ATEVs are also currently in late-stage clinical trials targeting other vascular applications, including arteriovenous (AV) access for hemodialysis and peripheral artery disease (PAD). Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte’s 6mm ATEV for AV access in hemodialysis was the first product candidate to receive the FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation and has also received FDA Fast Track designation. Humacyte’s 6mm ATEV for urgent arterial repair following extremity vascular trauma and for advanced PAD also have received RMAT designations. The ATEV received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense. For more information, visit www.Humacyte.com.

For uses other than the FDA approval in the extremity vascular trauma indication, the ATEV is an investigational product and has not been approved for sale by the FDA or any other regulatory agency.

Forward-Looking Statements

This press release contains forward-looking statements that are based on beliefs and assumptions and on information currently available. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties, and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements in this press release include, but are not limited to, our plans and ability to commercialize Symvess and, if approved by regulatory authorities, our product candidates, successfully and on our anticipated timelines; the degree of market acceptance of and the availability of third-party coverage and reimbursement for Symvess and, if approved by regulatory authorities, our product candidates; our ability to manufacture Symvess and, if approved by regulatory authorities, our product candidates in sufficient quantities to satisfy our clinical trial and commercial needs; the anticipated benefits of our ATEVs relative to existing alternatives; our plans and ability to execute product development, process development and preclinical development efforts successfully and on our anticipated timelines; our ability to design, initiate and successfully complete clinical trials and other studies for our product candidates and our plans and expectations regarding our ongoing or planned clinical trials; the anticipated characteristics and performance of our ATEVs; the implementation of our business model and strategic plans for our business; our ability to execute and achieve the expected benefits of our cost-saving measures and whether our efforts will result in further actions or additional asset impairment charges that adversely affect our business; and the timing or likelihood of regulatory filings, acceptances and approvals. We cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility that Humacyte may be adversely affected by other economic, business, competitive and/or reputational factors, and other risks and uncertainties, including those described under the header “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024 and Form 10-Q for the quarter ended March 31, 2025, each filed by Humacyte with the SEC, and in future SEC filings. Most of these factors are outside of Humacyte’s control and are difficult to predict. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. Except as required by law, we have no current intention of updating any of the forward-looking statements in this press release. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.

Humacyte Investor Contact:
Joyce Allaire
LifeSci Advisors LLC
+1-617-435-6602
jallaire@lifesciadvisors.com
investors@humacyte.com

Humacyte Media Contact:
Rich Luchette
Precision Strategies
+1-202-845-3924
rich@precisionstrategies.com
media@humacyte.com

FOSTER CITY, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) — Geron Corporation (Nasdaq: GERN), a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood cancer, today announced that members of the management team are scheduled to participate in a fireside chat and be available for one-on-one meetings at the Stifel 2026 Healthcare Conference on Tuesday, November 10, 2026 at 2:00 p.m. ET in New York, NY.

A live and archived audio webcast of the fireside chat will be available through the Investor section of Geron’s website at www.geron.com.

About Geron
Geron is a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood cancer. Because patients cannot wait, we approach our work with urgency, bringing together deep expertise in telomerase biology with patient perspectives and insights from clinical research and real-world care. Our medicine, RYTELO^® (imetelstat), is approved in the United States and European Union for certain patients with lower-risk myelodysplastic syndromes (LR-MDS). Geron is a commercial-stage company with offices in Parsippany, New Jersey and Foster City, California. To learn more, visit www.geron.com or follow us on LinkedIn.

Investors and Media
Dawn Schottlandt
Senior Vice President, Investor Relations and Corporate Affairs
dschottlandt@geron.com

CAMBRIDGE, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) — City Therapeutics, Inc. (Nasdaq: CTY), a clinical-stage biotechnology company developing the next generation of RNA interference (RNAi) therapeutics, today announced that management will participate in the following investor conferences in November.

Stifel 2026 Healthcare Conference
Fireside Chat: Tuesday, November 10, 2026, at 10:00 a.m. ET
Location: New York, New York

Jefferies Global Healthcare Conference in London
Presentation: Monday, November 16, 2026, at 1:00 p.m. GMT
Location: London, England

Live webcasts of the fireside chat and presentation will be available on the “News & Events” page within the Investors section of the City Therapeutics’ website at investors.citytx.com. A replay of the webcasts will be available for approximately 90 days.

About City Therapeutics
City Therapeutics is a clinical-stage biotechnology company engineering the next generation of RNA interference (RNAi) therapeutics, with the aim of delivering meaningful and durable benefits for patients in need. City’s lead development programs are CITY-FXI for thromboembolic diseases, CITY-RBP4 for Stargardt disease and other retinal diseases, and CITY-TFR2 for anemia associated with chronic diseases. The City Platform is the engine behind every therapeutic the company develops and integrates deep expertise in trigger engineering, including proprietary cityRNA triggers designed to address limitations of conventional RNAi approaches, tissue-selective delivery, and genetics-driven target selection. For more information, visit www.citytx.com and follow us on LinkedIn, X, and Bluesky.

Media Contact:
Katie Engleman, 1AB
katie@1abmedia.com

Investor Contact: 
Stephanie Ascher, Precision AQ
Stephanie.Ascher@precisionaq.com

SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) — Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that management will participate in the following investor conferences in November 2026 and will also participate in one-on-one investor meetings at each of these conferences.

Guggenheim 3^rd Annual Healthcare Innovation Conference
Location: InterContinental Boston, Boston, MA
Format: Fireside Chat
Date and Time: Tuesday, November 10, 3:30 pm Eastern Time

Stifel 2026 Healthcare Conference
Location: Lotte New York Palace, New York, NY
Format: Fireside Chat
Date and Time: Wednesday, November 11, 9:20 am Eastern Time

Jefferies Global Healthcare Conference
Location: The Waldorf Hilton, London, UK
Format: Fireside Chat
Date and Time: Wednesday, November 18, 12:30 pm Greenwich Mean Time

A live audio webcast of the events will be available online at Erasca.com/events. An archived replay of the events will be available for 30 days following the webcast at Erasca.com/events.

About Erasca
At Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of patients with cancer. We believe our team’s capabilities and experience, further guided by our scientific advisory board which includes the world’s leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer.

Contact:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com

Media Contact:
Michael Fitzhugh
LifeSci Communications
mfitzhugh@lifescicomms.com

• Potential to pay as little as $0 per fill for VOQUEZNA, plus free home delivery and prior authorization support, makes it simpler for GERD patients to get the medicine their doctor prescribed

A Media Snippet accompanying this announcement is available by clicking on this link.

FLORHAM PARK, N.J, Nov. 03, 2026 (GLOBE NEWSWIRE) — Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal diseases, today announced that eligible commercially insured patients may pay as little as $0 for VOQUEZNA^® (vonoprazan) tablets exclusively through BlinkRx, Phathom’s pharmacy network partner, subject to eligibility requirements, benefit limits, and program terms. The offer is part of Phathom’s broader efforts to make it easier and more affordable for patients with gastroesophageal reflux disease (GERD) to fill their VOQUEZNA prescriptions.

“We believe that patients with GERD who are prescribed VOQUEZNA should be able to start and stay on their medication, without unnecessary cost or paperwork getting in the way,” said Steve Basta, President and Chief Executive Officer of Phathom Pharmaceuticals. “By partnering with BlinkRx, we’re working to make VOQUEZNA easier and more affordable to access, with eligible commercially insured patients now having the potential to pay as little as $0, as well as continuing to offer a cash-pay option for those without insurance coverage. For many people living with GERD, finding the right treatment can be a long journey. Once their doctor prescribes VOQUEZNA, starting treatment should be the easy part. This initiative reflects our focus on putting patients first.”

How it works

• As little as $0: Commercially insured patients may pay as little as $0 for VOQUEZNA exclusively through BlinkRx, subject to eligibility requirements, benefit limits, and terms and conditions, whether their prescription is for a 30-, 60- or 90-day supply of VOQUEZNA 10 mg or 20 mg tablets.
• Lowest eligible cost, automatically: BlinkRx automatically identifies the lowest out-of-pocket cost available through its program, including the $0 offer when available for eligible patients, with no coupon or copay card to keep track of.
• Free home delivery and easy refills: VOQUEZNA ships directly to the patient’s door at no extra cost, and patients can schedule and receive refills without a trip to the pharmacy.
• Help with insurance requirements: BlinkRx coordinates directly with doctors’ offices on prior authorization and other insurance requirements, when needed, to help simplify the prescription process.

How to get started
Patients can ask their healthcare provider to send their prescription for VOQUEZNA tablets directly to BlinkRx U.S., Boise, Idaho. Once BlinkRx receives the prescription, patients will be sent a secure link by text or email to set up their BlinkRx patient profile and complete their order. Learn more at www.VOQUEZNA.com/cost-and-savings.

Who’s eligible for the $0 offer?
The $0 offer applies to VOQUEZNA tablets and is available to patients 18 years of age or older whose commercial insurance covers VOQUEZNA subject to eligibility requirements, benefit limits, and terms and conditions. The $0 offer is not available to patients whose prescriptions are paid for by a government health program as federal law prohibits Phathom from providing copay savings offers to such patients. The $0 offer is not available to Massachusetts residents, as state law does not permit manufacturer copay assistance that excludes or favors any pharmacy. Eligible commercially insured Massachusetts residents may pay as little as $25 for a 30-day supply, $50 for a 60-day supply, or $90 for a 90-day supply of VOQUEZNA with the VOQUEZNA Savings Card at BlinkRx or participating retail pharmacies.

Additional ways to save on VOQUEZNA
Retail pharmacies: Eligible patients with commercial insurance who prefer a retail pharmacy can continue to use the VOQUEZNA Savings Card and may pay as little as $25 for a 30-day supply, subject to eligibility requirements, benefit limits, and terms and conditions.

Cash-pay option: Eligible patients without insurance or whose insurance does not cover VOQUEZNA may pay as little as $55 for a 30-day supply through BlinkRx. This cash-pay option is only available through BlinkRx.

Phathom reserves the right to change or discontinue these offers at any time without notice. See full terms and learn more at www.VOQUEZNA.com/cost-and-savings.

About VOQUEZNA^® (vonoprazan)
VOQUEZNA^® (vonoprazan) tablets contain vonoprazan, an oral small molecule potassium-competitive acid blocker (PCAB). PCABs are a novel class of medicines that block acid secretion in the stomach. VOQUEZNA is approved in the U.S. for the treatment of adults with Erosive Esophagitis, also known as Erosive GERD, the relief of heartburn associated with Erosive GERD, and the relief of heartburn associated with Non-Erosive GERD. Phathom in-licensed the U.S. rights to vonoprazan from Takeda, which markets the product in Japan and numerous other countries in Asia and Latin America.

INDICATION AND IMPORTANT SAFETY INFORMATION

What is VOQUEZNA?

• VOQUEZNA^® (vonoprazan) is a prescription medicine used in adults:
  • for 8 weeks to heal acid-related damage to the lining of the esophagus (called Erosive Esophagitis) and for relief of heartburn related to Erosive Esophagitis.
  • for up to 6 months to maintain healing of Erosive Esophagitis and for relief of heartburn related to Erosive Esophagitis.
  • for 4 weeks for relief of heartburn related to gastroesophageal reflux disease (GERD).

It is not known if VOQUEZNA is safe and effective in children.

Do not take VOQUEZNA if you:

• are allergic to vonoprazan or any of the other ingredients in VOQUEZNA. Allergic reaction symptoms may include trouble breathing, rash, itching, and swelling of your face, lips, tongue or throat.
• are taking a medicine that contains rilpivirine (EDURANT, COMPLERA, JULUCA, ODEFSEY) used to treat HIV-1 (Human Immunodeficiency Virus).

Before taking VOQUEZNA, tell your healthcare provider about all your medical conditions, including if you:

• have low magnesium, calcium, or potassium in your blood, or you are taking a medicine to increase urine (diuretic).
• have kidney or liver problems.
• are pregnant, think you may be pregnant, or plan to become pregnant. It is not known if VOQUEZNA will harm your unborn baby.
  • Pregnancy Exposure Registry: There is a pregnancy registry for women who take VOQUEZNA during pregnancy. The purpose of this registry is to collect information about the health of you and your baby. If you are pregnant or become pregnant during treatment with VOQUEZNA, talk to your healthcare provider about how you can join this pregnancy registry or you can enroll in the registry by calling 1-866-609-1612 or visiting https://voqueznapregnancyregistry.com/.
• are breastfeeding or plan to breastfeed. You and your healthcare provider should decide if you will take VOQUEZNA while breastfeeding.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.

VOQUEZNA may affect how other medicines work, and other medicines may affect how VOQUEZNA works. Especially tell your healthcare provider if you take medicine that contains rilpivirine (EDURANT, COMPLERA, JULUCA, ODEFSEY).

What are the possible side effects of VOQUEZNA?

VOQUEZNA may cause serious side effects including:

• A type of kidney problem (acute tubulointerstitial nephritis): Some people who take VOQUEZNA may develop a kidney problem called acute tubulointerstitial nephritis. Call your healthcare provider right away if you have a decrease in the amount that you urinate or if you notice blood in your urine.
• Diarrhea caused by an infection (Clostridioides difficile) in your intestines: Call your healthcare provider right away if you have watery stools, stomach pain, and fever that does not go away.
• Bone fractures (hip, wrist, or spine): Bone fractures in the hip, wrist, or spine may happen in people who take multiple daily doses of another type of medicine that reduces acid in your stomach known as proton pump inhibitors (PPI medicines) for a long period of time (a year or longer). Tell your healthcare provider if you have a bone fracture, especially in the hip, wrist, or spine.
• Severe skin reactions: VOQUEZNA can cause rare, but severe skin reactions that may affect any part of your body. These serious skin reactions may need to be treated in a hospital and may be life threatening:
  • Skin rash which may have blistering, peeling, or bleeding on any part of your skin.
  • You may also have fever, chills, body aches, shortness of breath, or enlarged lymph nodes.

   If you experience any of these symptoms, stop taking VOQUEZNA and call your healthcare provider right away. These symptoms may be the first sign of a severe skin reaction.

• Low vitamin B-12 levels: VOQUEZNA lowers the amount of acid in your stomach. Stomach acid is needed to absorb Vitamin B12 properly. Tell your healthcare provider if you have symptoms of low vitamin B12 levels, including irregular heartbeat, shortness of breath, lightheadedness, tingling or numbness in the arms or legs, muscle weakness, pale skin, feeling tired, or mood changes. Talk with your healthcare provider about the risk of low vitamin B12 levels if you have been on VOQUEZNA for a long time.
• Low magnesium levels in the body can happen in people who take VOQUEZNA. Tell your healthcare provider right away if you have symptoms of low magnesium levels, including seizures, dizziness, irregular heartbeat, jitteriness, muscle aches or weakness, or spasms of the hands, feet, or voice.
• Stomach growths (fundic gland polyps): A certain type of stomach growth called fundic gland polyps may happen in people who take another type of medicine that reduces acid in your stomach known as proton pump inhibitors (PPI medicines) for a long time. Talk with your healthcare provider about the possibility of fundic gland polyps if you have been on VOQUEZNA for a long time.

The most common side effects of VOQUEZNA for treatment of Erosive Esophagitis or relief of heartburn related to gastroesophageal reflux disease include:

• stomach inflammation
• diarrhea
• stomach bloating
• stomach pain
• nausea
• indigestion
• constipation
• high blood pressure
• urinary tract infection

These are not all the possible side effects of VOQUEZNA. For more information, ask your healthcare provider or pharmacist. Call your healthcare provider for medical advice about side effects.

You are encouraged to report suspected adverse reactions by contacting Phathom Pharmaceuticals at 1-888-775-PHAT (7428) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see Patient Information and full Prescribing Information for VOQUEZNA.

About Gastroesophageal Reflux Disease (GERD)
Gastroesophageal reflux disease (GERD) is a chronic condition in which stomach acid flows back into the esophagus. An estimated 15 million U.S. adults are treated for GERD with a prescription medication. GERD has two main forms. Non-Erosive GERD, the most common form, causes symptoms such as frequent heartburn, regurgitation, difficulty swallowing and chest pain without visible damage to the esophagus. Erosive GERD, also called Erosive Esophagitis, involves erosions in the lining of the esophagus caused by stomach acid and, when inadequately treated, can progress to more serious conditions, including Barrett’s esophagus and esophageal cancer.

About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB), for the U.S., Europe and Canada. Phathom currently markets vonoprazan in the United States as VOQUEZNA^® (vonoprazan) tablets for the relief of heartburn associated with Non-Erosive GERD in adults, the healing and maintenance of healing of Erosive GERD in adults and relief of associated heartburn. For more information about Phathom, visit the company’s website at www.phathompharma.com and follow on LinkedIn and X.

Forward-looking Statements
This press release contains forward-looking statements within the meaning of applicable securities laws, including statements regarding our patient access initiatives and the anticipated benefits of our programs with BlinkRx, including the potential to improve the affordability and accessibility of VOQUEZNA and facilitate the ability of patients to obtain and continue treatment. These forward-looking statements are based on our current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied, including the risk that: changes in insurance coverage or reimbursement policies could limit patients’ ability to access VOQUEZNA or increase their out-of-pocket costs; patients may not qualify for or fully benefit from Phathom’s patient access programs; Phathom may modify, limit or discontinue these programs; or changes in applicable laws or regulations could restrict the availability or operation of these programs. Additional risks and uncertainties related to our business are described in our filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K. Phathom undertakes no obligation to update any forward-looking statements, except as required by law.

MEDIA CONTACT
Nick Benedetto
1-877-742-8466
media@phathompharma.com

INVESTOR CONTACT
Eric Sciorilli
1-877-742-8466
IR@phathompharma.com

© 2026 Phathom Pharmaceuticals. All rights reserved. VOQUEZNA, Phathom Pharmaceuticals, and their respective logos are registered trademarks of Phathom Pharmaceuticals, Inc.

11/26 US-VPZ-26-0354

SUGAR LAND, Texas, Nov. 03, 2026 (GLOBE NEWSWIRE) — Team, Inc. (NYSE: TISI) (“TEAM” or the “Company”), a global, leading provider of specialty industrial services offering customers access to a full suite of conventional, specialized, and proprietary inspection, heat-treating, and mechanical services, today announced that it will issue its third quarter 2026 earnings release on Wednesday, November 11, 2026, after the close of trading on the New York Stock Exchange. TEAM will host a conference call to discuss its financial and operational results on Thursday morning, November 12, 2026, at 8:00 a.m. Central Time (9:00 a.m. Eastern Time).

Interested parties in the United States may participate toll-free by dialing (877) 270-2148. Interested parties internationally may dial (412) 902-6510. Participants should ask to join “TEAM, Inc. Third Quarter 2026 Conference Call.” This call will also be webcast on TEAM’s website at www.teaminc.com. An audio replay will be available on the Company’s website following the call.

The call will include a question-and-answer session, and investors are welcome to send questions to TISI@alpha-ir.com ahead of the scheduled call.

About Team, Inc.
Headquartered in Sugar Land, Texas, Team, Inc. (NYSE: TISI) is a global, leading provider of specialty industrial services offering customers access to a full suite of conventional, specialized, and proprietary inspection, heat-treating, and mechanical services. We deploy conventional to highly specialized inspection, condition assessment, maintenance, and repair services that result in greater safety, reliability, and operational efficiency for our customers’ most critical assets. Through locations in 13 countries, we unite the delivery of technological innovation with over a century of progressive, yet proven integrity and reliability management expertise to fuel a better tomorrow. For more information, please visit www.teaminc.com.

Contact:
Alpha Advisory Group
Nick Teves or Joseph Caminiti
TISI@alpha-ir.com

• Two Invited Presentations Showcase Clinical Progress in Solid Tumors and Allogene’s Broader Vision in Oncology and Autoimmune Disease
• Preclinical Poster Features Next-Generation DLL3/CD70 Dual CAR T Product Candidate for Small Cell Lung Cancer and Other Neuroendocrine Tumors, Demonstrating Continued Innovation with Dagger^® Technology

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) — Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced its participation in the Society for Immunotherapy of Cancer (SITC) Annual Meeting in Phoenix, Arizona. The Company’s participation includes two invited presentations and a preclinical poster showcasing the breadth and continued evolution of its platform.

“Our presence at SITC underscores the promise of our off-the-shelf CAR T platform, from clinical progress in solid tumors to next-generation innovation informed by learnings across our pipeline,” said Zachary Roberts, M.D., Ph.D., President and Chief Executive Officer of Allogene Therapeutics. “We are building on this experience to develop a new generation of cell therapies with the potential to expand patient access, reach more treatment settings and transform care across oncology and autoimmune disease.”

Scientific Presentation: Advancing a First-in-Class Allogeneic CAR T Approach in Renal Cell Carcinoma: Clinical Experience from the TRAVERSE Study
Thursday, November 5, 2026
9:05-9:15 a.m. MT
Jeffrey McLeroy, M.D.
Session I: Cell Therapies and Technologies
Sheraton, 2nd Level – Valley of the Sun Ballroom

Scientific Presentation: Allogeneic CAR T: A Platform Built for Patient Access – in Cancer and Beyond
Friday, November 6, 2026
4:25-4:40 p.m. MT
Zachary Roberts, M.D., Ph.D.
Biotech Session 107b: Next Generation of Off the Shelf I/O
Phoenix Convention Center, North Building, 300 Level, Halls BC

Complementing these presentations, the Company will present preclinical data evaluating a novel off-the-shelf DLL3/CD70 dual CAR T product candidate for small cell lung cancer and other neuroendocrine tumors. The findings suggest that careful selection of the genomic location for site-specific-integration of the CAR can improve CAR T cell performance in controlling tumors. Confirming and extending observations presented earlier this year with BCMA, the data show pairing the DLL3 CAR with a CAR targeting CD70 can enhance resistance to immune-mediated rejection, illustrating that Dagger^® technology can be coupled with other CARs. These findings reinforce the potential of the Dagger technology as a versatile foundation for Allogene’s next-generation pipeline, supporting the development of off-the-shelf CAR T therapies across additional targets for both hematological and solid tumors as well as autoimmune disease.

Poster: Off-the-shelf DLL3/CD70 dual CAR T cells with optimized site-specific integration for SCLC and neuroendocrine tumors
Friday, November 6, 2026
Abstract #207
12:15-1:45 p.m. MT and 5:30-7:00 p.m. MT
Presenter: Zhe Li, Ph.D.
Phoenix Convention Center, North Building, Lower Level, Exhibition Halls 4-5

About Allogene Therapeutics
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T) products for cancer and autoimmune disease. Led by cell therapy veterans applying proven CAR T experience, Allogene is developing a pipeline of off-the-shelf CAR T cell product candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit www.allogene.com, and follow Allogene Therapeutics on X and LinkedIn.

Cautionary Note on Forward-Looking Statements for Allogene
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things Allogene’s ability to develop and deliver readily available allogeneic CAR T products for the treatment of cancer and autoimmune disease on-demand, more reliably, and at greater scale to more patients. Various factors may cause material differences between Allogene’s expectations and actual results, including risks and uncertainties related to the early stage of development of Allogene’s next-generation product candidates; the possibility that preclinical findings, including those relating to the DLL3/CD70 dual CAR T product candidate and Dagger technology, may not translate into clinical results; uncertainties regarding the safety, efficacy and ability of Allogene’s product candidates to achieve meaningful clinical benefit; challenges in developing and applying novel CAR T technologies across different targets, indications and patient populations; and uncertainties regarding the timing, cost and success of clinical development and regulatory approval of Allogene’s product candidates. These and other risks are discussed in greater detail in Allogene’s filings with the SEC, including without limitation under the “Risk Factors” heading in its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Dagger^® is a trademark of Allogene Therapeutics, Inc.

Allogene’s investigational AlloCAR T oncology products utilize Cellectis technologies. Cemacabtagene ansegedleucel (cema-cel) was developed based on an exclusive license granted by Cellectis to Servier. Servier has granted Allogene exclusive rights to cema-cel in the U.S., all EU Member States and the United Kingdom. The anti-CD70 AlloCAR T program is licensed exclusively from Cellectis by Allogene and Allogene holds global development and commercial rights to this AlloCAR T program. ALLO-329 (CD19/CD70) in autoimmune disease uses CRISPR gene-editing technology. 

Allogene Media/Investor Contact:
Christine Cassiano
EVP, Chief Corporate Affairs & Brand Strategy Officer
Christine.Cassiano@allogene.com

Leslie Bryant
Executive Director, Corporate Communications
Leslie.Bryant@allogene.com

Global integration gives advertisers access to native, real-time AU reporting across web and CTV, plus automated attention-threshold optimization

NEW YORK, Nov. 03, 2026 (GLOBE NEWSWIRE) — Teads (NASDAQ: TEAD), the omnichannel outcomes platform, today announced the expansion of its partnership with Adelaide, the leader in attention-based media quality measurement. The integration brings Adelaide’s AU metric, which predicts a placement’s likelihood of capturing attention and driving outcomes, directly into Teads Ad Manager (TAM), enabling advertisers to measure, analyze, and optimize campaigns for media quality in real time across both web and CTV InStream formats.

Through this platform integration, advertisers can activate Adelaide measurement with a single click and view real-time AU data alongside standard delivery metrics such as viewability, video views, and click-through rates. Reporting includes detailed breakdowns by ad format, device, and placement. Additionally, Teads’ Attention Threshold optimization feature can be used to set an AU floor, automatically filtering out low-attention inventory to improve campaign efficiency and performance.

“Our priority is to give advertisers frictionless access to the industry’s leading media quality metrics directly within our platform,” said Neala Brown, Global Head of Data, Measurement, and Insights at Teads. “By natively embedding Adelaide’s AU metrics and automated optimization capabilities into Teads Ad Manager, we are empowering our clients to eliminate media waste and maximize campaign effectiveness across web and CTV inventory at scale.”

“To move the industry forward, media quality measurement must be both accessible and actionable,” said Marc Guldimann, CEO and Co-founder of Adelaide. “This partnership gives Teads advertisers the ability to evaluate media quality in real time and automatically optimize toward higher-AU inventory. By bringing an outcome-trained quality signal directly into optimization, we’re helping brands invest in inventory that is more likely to deliver meaningful business results.”

Key benefits for advertisers include:

• A richer view of media quality and attention potential, with granular, real-time visibility into how campaigns perform across both web and CTV InStream formats, broken down by format, device, and placement.
• More accountable media decisions, with Adelaide AU reported alongside standard metrics like viewability, video views, and CTR directly within Teads Ad Manager (TAM) to help eliminate media waste and connect exposure with quality.
• A stronger foundation for quality-based optimization, allowing advertisers to activate automated Attention Threshold optimization to set an AU floor, filter out low-attention inventory, and prioritize placements that are more likely to drive full-funnel business outcomes.

Availability

Adelaide AU measurement is available globally in Teads Ad Manager (TAM).

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws, which statements involve substantial risks and uncertainties. Forward-looking statements generally relate to possible or assumed future results of our business, financial condition, results of operations, liquidity, plans and objectives. You can generally identify forward-looking statements because they contain words such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “guidance,” “outlook,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “foresee,” “potential” or “continue” or the negative of these terms or other similar expressions that concern our expectations, strategy, plans or intentions.

We have based these forward-looking statements largely on our current expectations and projections regarding future events and trends that we believe may affect our business, financial condition and results of operations. The outcome of the events described in these forward-looking statements is subject to risks, uncertainties and other factors, including but not limited to: the risk that our integration with Adelaide may not yield the anticipated commercial benefits, advertiser adoption, or campaign performance optimizations as expected; technical and operational challenges related to maintaining real-time AU reporting across web and CTV formats; the highly competitive nature of the digital, CTV, and streaming advertising markets; and the other important risks described in the section entitled “Risk Factors” and elsewhere in the Annual Report on Form 10-K filed for the year ended December 31, 2025, and our Quarterly Reports on Form 10-Q filed for the quarters ended March 31, 2026, and June 30, 2026, filed with the Securities and Exchange Commission (the “SEC”), which are available on our website at https://investors.teads.com/ and on the SEC’s website at www.sec.gov.

Accordingly, you should not rely upon forward-looking statements as predictions of future events. We cannot assure you that the results, events and circumstances reflected in the forward-looking statements will be achieved or occur, and actual results, events or circumstances could differ materially from those projected in the forward-looking statements. We undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events. We do not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

About Adelaide
Adelaide is the leader in attention-based media quality measurement. Our mission is to bring increased transparency and fairness to advertising by supplying the market with a precise, omnichannel media quality metric connected to business outcomes. Adweek has called Adelaide’s AU “the attention economy’s most widely recognized metric.” Proven to predict full-funnel outcomes more accurately than any existing metric, AU helps the world’s largest brands make smarter investment decisions, activate attention data programmatically, and drive better performance. Adelaide is named after the global epicenter of evidence-based marketing in southern Australia and headquartered in New York City. For more information, visit adelaidemetrics.com.

About Teads
Teads Holding Co. (“Teads”) (Nasdaq: TEAD) is a leading omnichannel advertising platform focused on driving outcomes for brand and performance advertisers across screens. With a focus on meaningful business outcomes for full funnel objectives, Teads drives value by leveraging predictive AI technology to connect quality media, beautiful brand creative, and context-driven addressability and measurement. Teads is directly partnered with more than 10,000 publishers and 20,000 advertisers globally. The company is headquartered in New York, New York, with a global team of around 1,700 people in 30+ countries.

For more information, visit www.teads.com.

Media Contact
press@teads.com

Investor Relations Contact
IR@teads.com
(332) 205-8999

Funding provided through the Bank’s Community Development Partnership Program

ISELIN, N.J., Nov. 03, 2026 (GLOBE NEWSWIRE) — Provident Bank, a leading New Jersey-based financial institution, announced today that it has awarded $83,000 in grants to ten local non-profit organizations through its Community Development Partnership Program. The grants will advance financial literacy education, affordable housing, homeownership, and help meet the credit needs of the communities served.

The Community Development Partnership Program builds on Provident Bank’s long record of working alongside non-profits to strengthen the communities it serves and foster lasting economic prosperity.

Combined, the recipients of these major grants received a total of $83,000. The local non-profit organizations include:

• Central Jersey Housing Resource Center: Supports households facing challenges by helping them find safe, affordable housing that meets their needs.
• Clinton Hill Community Action: Partners with residents to revitalize the Clinton Hill neighborhood and ensure that development is equitable and just.
• Habitat for Humanity of Greater Newark: Builds affordable housing for families with low to moderate incomes through new construction, home rehabilitation, and neighborhood revitalization.
• Housing & Community Development Network of New Jersey: Dedicated to advancing economic justice, empowering low-income communities, and fostering inclusive participation in public policy.
• Housing Partnership: Creates lasting and responsible homeownership through education and financial coaching.
• Ironbound Community Corporation: Engages and empowers individuals, families, and groups to achieve their aspirations and collaboratively build a community.
• New Jersey Community Capital: Creating communities through strategic investments and knowledge.
• NORWESCAP: Strengthens communities by creating opportunities that improve the lives of low-income individuals and families.
• Urban League of Essex County: Empowering African Americans and disadvantaged residents to achieve social and economic self-sufficiency through programs in education, employment, housing, and economic development that transform lives and communities.
• Urban League of Union County: Assists the community in achieving social and economic equality by providing resources and support services.

“This year we’re able to support more organizations with a larger investment, and that reflects how much need and opportunity there is across our communities,” said Roxanne Camejo, Senior Vice President, Community Development Officer, Provident Bank. “These partners are delivering real results in housing, education and financial empowerment, and we’re proud to stand alongside them.”

Since July 2023, Provident Bank has partnered with more than a dozen local non-profit organizations through the Community Development Partnership Program, all sharing a common goal of fostering economic opportunity and sustainable community growth.

Through the Community Development Partnership Program, Provident Bank continues to invest in organizations that help New Jersey residents buy homes, build financial skills, and access new opportunities, laying the groundwork for stronger, more inclusive communities.

About Provident Bank

Founded in Jersey City in 1839, Provident Bank is the oldest community-focused financial institution based in New Jersey and is the wholly owned subsidiary of Provident Financial Services, Inc. (NYSE:PFS). With assets of $25.85 billion as of September 30, 2026, Provident Bank offers a wide range of customized financial solutions for businesses and consumers with an exceptional customer experience delivered through its convenient network of 135 branches across New Jersey and parts of New York and Pennsylvania, via mobile and online banking, and from its customer contact center. The bank also provides fiduciary and wealth management services through its wholly owned subsidiary, Beacon Trust Company, and insurance services through its wholly owned subsidiary, Provident Protection Plus, Inc. To learn more about Provident Bank, go to www.provident.bank or call our customer contact center at 800.448.7768.

Media Contacts:
Provident Bank
Keith Buscio, Director Public Relations & Communications
Keith.Buscio@provident.bank

Vested
Providentbank@fullyvested.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/4d8d2f14-9deb-4bb7-bb79-3a6266609450